The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement.
The partners announced in January 2023 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted a marketing authorization for Ximluci (ranibizumab), a biosimilar referencing Lucentis. Under the co-development agreement in operation since 2018, STADA is responsible for commercializing Ximluci across Europe, while Xbrane is responsible for commercial supply of the product. The parties are sharing profits generated from sales of the product equally. In early April 2023, the partners announced the launch of Ximluci in several European countries.
Treatment of retinal vascular disorders
Ximluci is an anti-VEGF (vascular endothelial growth factor) for the treatment of retinal vascular disorders, including wet age-related macular degeneration (wet AMD), diabetic macular oedema (DME), diabetic retinopathy (PDR), retinal vein occlusion (RVO) and visual impairment due to choroidal neovascularization (CNV) in adults.
“We are proud of our partner STADA being awarded as supplier under this important framework agreement. Ximluci will, during the coming 12 months, generate significant savings to the UK healthcare system and broaden accessibility to patients,” stated Martin Åmark, Xbrane CEO.
STADA’s UK affiliate Thornton and Ross is one two companies awarded in NHS Framework Agreement that covers a substantial portion of clinical demand for ranibizumab in England. While the nominal total value of this supply contract, which runs from 1 April 2023 to 31 March 2024, is £70 million (€79 million), the actual value to STADA and Xbrane will depend on multiple factors, including the ability to capture share within the market segment covered by the Framework Agreement.
Photo of Martin Åmark: Xbrane
